Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing therapies for solid tumors and blood-related cancers. Co.'s programs, including ADCETRIS and PADCEV, are based on its antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The SGEN stock yearly return is shown above.
The yearly return on the SGEN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SGEN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|